• LOGIN
    Login with username and password
Repository logo

BORIS Portal

Bern Open Repository and Information System

  • Publications
  • Projects
  • Funding
  • Research Data
  • Organizations
  • Researchers
  • LOGIN
    Login with username and password
Repository logo
Unibern.ch
  1. Home
  2. Publications
  3. Impact of early versus deferred antiretroviral therapy on estimated glomerular filtration rate in HIV-positive individuals in the START trial.
 

Impact of early versus deferred antiretroviral therapy on estimated glomerular filtration rate in HIV-positive individuals in the START trial.

Options
  • Details
BORIS DOI
10.7892/boris.101872
Date of Publication
September 2017
Publication Type
Article
Division/Institute

Universitätsklinik fü...

Contributor
Achhra, Amit C
Mocroft, Amanda
Ross, Michael
Ryom-Nielson, Lene
Avihingsanon, Anchalee
Bakowska, Elzbieta
Belloso, Waldo
Clarke, Amanda
Furrer, Hansjakoborcid-logo
Universitätsklinik für Infektiologie
Lucas, Gregory M
Ristola, Matti
Rassool, Mohammed
Ross, Jonathan
Somboonwit, Charurut
Sharma, Shweta
Wyatt, Christina
Subject(s)

600 - Technology::610...

Series
International journal of antimicrobial agents
ISSN or ISBN (if monograph)
0924-8579
Publisher
Elsevier
Language
English
Publisher DOI
10.1016/j.ijantimicag.2017.04.021
PubMed ID
28668686
Uncontrolled Keywords

CKD HAART HIV START e...

Description
BACKGROUND

Both untreated HIV infection and antiretroviral therapy (ART) have been associated with worsening kidney function. The impact of earlier ART initiation on kidney function has not been studied.

METHODS

The START trial was a randomized comparison of immediate versus deferred ART initiation among HIV+ persons with CD4+ counts >500 cells/mm(3). Serum creatinine and urine dipstick protein were measured at baseline, months 1, 4, 8, 12, and annually thereafter. We compared the two arms for changes in estimated glomerular filtration rate (eGFR, using the CKD-EPI equation) over time using longitudinal mixed models.

FINDINGS

Of 4685 START participants, 4629 (n=2294 in immediate and 2335 in deferred arm) individuals were included. Median baseline CD4 and eGFR were 651 cells/mm(3) and 111⋅5 mL/min/1⋅73m(2). ART was initiated in 2271 participants (99%) in the immediate and 1127 participants (48%) in the deferred arm, accounting for over 94% and 19% of follow-up time, respectively. Overall, 89% started ART using a tenofovir-based regimen. Over a median follow-up of 2⋅1 years, the mean eGFR was 0⋅56 (95% CI: 0⋅003-1⋅11) mL/min/1⋅73m(2) higher in the immediate arm than the deferred arm. This difference was more prominent after adjustment for current use of tenofovir or boosted-protease inhibitors (1⋅85, 95% CI: 1⋅21-2⋅50), and was more prominent in participants of black race (30% overall) (3⋅90, 95% CI: 2⋅84-4⋅97) compared to non-black (1⋅05, 95% CI: 0⋅33-1⋅77) (p<0⋅001 for interaction). Relative risk for proteinuria in the immediate vs. deferred arm was 0⋅74 (95% CI: 0⋅55-1⋅00), P=0⋅049. The incidence of chronic kidney disease as defined by eGFR < 60 or dipstick proteinuria was low, and there was no significant difference between treatment arms (incidence rate ratio 0.79, 95% CI 0.59-1.05).

CONCLUSION

In the short-term, immediate ART initiation was associated with a modestly higher eGFR and lower risk of proteinuria as opposed to deferring ART- a difference more pronounced in those with black race. Whether this early benefit translates into a lower risk of chronic kidney disease requires further follow-up.
Handle
https://boris-portal.unibe.ch/handle/20.500.12422/153661
Show full item
File(s)
FileFile TypeFormatSizeLicensePublisher/Copright statementContent
1-s2.0-S0924857917302303-main.pdftextAdobe PDF1.11 MBAttribution-NonCommercial-NoDerivatives (CC BY-NC-ND 4.0)acceptedOpen
1-s2.0-S0924857917302303-main.pdftextAdobe PDF895.28 KBpublisherpublished
BORIS Portal
Bern Open Repository and Information System
Build: 27ad28 [15.10. 15:21]
Explore
  • Projects
  • Funding
  • Publications
  • Research Data
  • Organizations
  • Researchers
More
  • About BORIS Portal
  • Send Feedback
  • Cookie settings
  • Service Policy
Follow us on
  • Mastodon
  • YouTube
  • LinkedIn
UniBe logo